On January 4, 2018 Shire plc (LSE: SHP, NASDAQ: SHPG) reported that Flemming Ornskov, M.D., M.P.H., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in in San Francisco, California on Monday, January 8th, 2018, at 10:30 AM Pacific Standard Time (18:30 GMT) (Press release, Shire, JAN 4, 2018, View Source [SID1234522894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and the questions & answers session will be available on Shire’s Investor website at View Source Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.

On January 4, 2018 Dynavax Technologies Corporation (NASDAQ:DVAX) reported that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA (Press release, Dynavax Technologies, JAN 4, 2018, View Source [SID1234522868]). The presentation will be webcast live and will occur on Thursday, January 11, 2018 at 7:30 a.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website at www.dynavax.com.

On January 4, 2018 Cue Biopharma, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, reported that it will be featured as a presenting company at the upcoming 10th Annual Biotech Showcase Conference on January 9, 2018, in San Francisco, CA (Press release, Cue Biopharma, JAN 4, 2018, View Source [SID1234522915]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Date: Tuesday, January 9, 2018

Time: 11:15 am PT

Duration: 15 minutes

Location: Franciscan Room B at the Ballroom Level of the Hilton San Francisco Union Square

Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma, will provide an overview of the Company’s technology platform and overall development strategy and give updates on key programs, including anticipated development milestones.

On January 4, 2018 CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, reported they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics (Press release, CureVac, JAN 4, 2018, View Source [SID1234522914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on mRNA Therapeutics in Oncology, book your free 1stOncology demo here.

Under the agreement, the companies will collaborate to develop up to four molecular therapy products for rare diseases using Curevac’s optimized natural mRNA sequence (RNAoptimizer) and Arcturus’s lipid-mediated nucleic acid delivery system (LUNAR). The agreement focuses on developing mRNA therapeutics for enzyme replacement and antibody generation. Development costs will be shared between the companies, with plans to co-commercialize products in the future under a profit sharing arrangement. The first mRNA therapy to be jointly developed and potentially commercialized by the companies will target ornithine transcarbamylase (OTC) deficiency, a genetic disease characterized by the accumulation of ammonia in the blood. The collaboration also grants CureVac access to the full suite of Arcturus’s lipid-mediated delivery intellectual property to enable the development of additional mRNA product candidates.

"This collaboration for up to four products establishes a sound relationship with Arcturus, which we believe is one of the leaders in developing lipid-mediated delivery systems for mRNA molecules," said Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac. "Just as important, we are excited to have secured access to Arcturus’s leading intellectual property rights for future product development in molecular therapies. This partnership combines both companies’ technology platforms with the expertise necessary to develop the next generation of therapeutics based on the considerable potential of mRNA."

"We are thrilled to combine Arcturus’s platform technologies and expertise with CureVac’s recognized capabilities in mRNA construct optimization and GMP manufacturing to co-develop messenger RNA medicines for patients in need," said Joseph Payne, President and CEO of Arcturus. "We believe our collaboration with CureVac has the potential to help reduce costs, mitigate manufacturing risks, and accelerate our timelines for ushering quality mRNA medicines into the clinic."

On January 4, 2018 SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, reported that it will present at the 36th Annual J.P. Morgan Healthcare Conference (Press release, SpringWorks Therapeutics, JAN 4, 2018, View Source [SID1234538854]). Lara S. Sullivan, M.D., President and Founder, and Saqib Islam, Chief Financial Officer and Chief Business Officer, are scheduled to present at 1:30 p.m. PT on Tuesday, January 9, 2017 at the Westin St. Francis in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Having launched SpringWorks Therapeutics only four months ago, we are honored to have been selected to present at the J.P. Morgan Healthcare Conference," stated Mr. Islam. "Our collaborative, patient-centric business model is providing innovative ways to advance promising, investigational therapies that may be otherwise trapped on the sidelines in larger pharmaceutical and biotech companies. We look forward to sharing highlights of our novel approach and late-stage pipeline as we enter a catalyst-rich 2018."